Barclays Maintains Overweight on Amedisys, Lowers Price Target to $213
Barclays analyst Steve Valiquette maintains Amedisys (NASDAQ:AMED) with a Overweight and lowers the price target from $236 to $213.
Analyst Ratings For Amedisys
Over the past 3 months, 11 analysts have published their opinion on Amedisys (NASDAQ:AMED) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Raymond James Maintains Outperform on Amedisys, Lowers Price Target to $225
Raymond James analyst John Ransom maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $250 to $225.
What 12 Analyst Ratings Have To Say About Amedisys
Amedisys (NASDAQ:AMED) has observed the following analyst ratings within the last quarter:
Credit Suisse Maintains Outperform on Amedisys, Raises Price Target to $205
Credit Suisse analyst Jonathan Yong maintains Amedisys (NASDAQ:AMED) with a Outperform and raises the price target from $192 to $205.
SVB Leerink Maintains Market Perform on Amedisys, Raises Price Target to $181
SVB Leerink analyst Whit Mayo maintains Amedisys (NASDAQ:AMED) with a Market Perform and raises the price target from $170 to $181.
Analyst Ratings For Amedisys
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings:
Amedisys Q3 Adj. EPS $1.53 Beats $1.36 Estimate, Sales $553.50M Miss $568.37M Estimate
Amedisys (NASDAQ:AMED) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.36 by 12.5 percent. This is a 31.7 percent decrease over earnings of $2.24 per share from the same
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
